Autoimmune cytopenia

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Tillman Benjamin-2.jpg
Benjamin Tillman, MD
Vanderbilt University
Nashville, TN, USA


This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.

  • We have moved How I Treat articles to a dedicated page.
2 regimens on this page
2 variants on this page

Relapsed or refractory

Alemtuzumab monotherapy


Study Evidence Efficacy
Willis et al. 2001 Phase 2 ORR: 71%

Immunosuppressive therapy

  • Alemtuzumab (Campath) as follows:
    • Test dose: 1 mg IV over 60 minutes once
    • Days 1 to 10: 10 mg IV over 4 hours once per day

10-day course


  1. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains dosing details in manuscript PubMed

Sirolimus monotherapy


Study Evidence Efficacy
Bride et al. 2015 Phase 2 Durable CR observed in patients with ALPS

Immunosuppressive therapy

6-month course, extended for those with a favorable response

Dose and schedule modifications

  • See manuscript for recommended dose adjustments


  1. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains dosing details in abstract PubMed